The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease

被引：42

作者：

Corte, Tamera J. ^{[1
]}

Gatzoulis, Michael A. ^{[1
]}

Parfitt, Lisa ^{[1
]}

Harries, Carl ^{[1
]}

Wells, Athol U. ^{[1
]}

Wort, S. John ^{[1
]}

机构：

[1] Royal Brompton Hosp, Pulm Hypertens Unit, London SW3 6NP, England

来源：

RESPIROLOGY | 2010年 / 15卷 / 08期

关键词：

brain natriruretic peptide; interstitial lung disease; pulmonary hypertension; sildenafil; 6-minute walk test; CLINICAL-TRIAL DESIGN; ARTERIAL-HYPERTENSION; PHOSPHODIESTERASE TYPE-5; COMBINATION THERAPY; INHALED ILOPROST; END-POINTS; FIBROSIS; ENDOTHELIN-1; SARCOIDOSIS; PRESSURE;

D O I：

10.1111/j.1440-1843.2010.01860.x

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background and objective: Limited data suggest a benefit following sildenafil treatment in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD). The role of sildenafil in the management of PH in ILD is not clear. We report our experience of ILD patients with PH after 6-month sildenafil therapy. Methods: We reviewed 15 patients (mean age 55 +/- 15 years; 8 men) with ILD (mean FVC 52.6 +/- 15.4%) and PH (mean right ventricular systolic pressure 73.8 +/- 17.8 mm Hg). Median brain natriuretic peptide: 37 (5-452) pmol/L; mean 6MWD: 156 +/- 101 m. Results: Following 6-month treatment with sildenafil, brain natriuretic peptide levels were lower (n = 12, P = 0.03), 6MWD was higher (n = 6, P < 0.05), but no change in right ventricular systolic pressure (n = 11) was demonstrated. Conclusions: Our observations suggest that sildenafil may be useful in the management of PH in ILD. Controlled trials are warranted before therapeutic recommendations can be made.

引用

页码：1226 / 1232

页数：7

共 63 条

[1]

Agarwal R, 2005, Indian J Chest Dis Allied Sci, V47, P267

[2] Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease [J].

Arcasoy, SM ;

Christie, JD ;

Ferrari, VA ;

Sutton, MS ;

Zisman, DA ;

Blumenthal, NP ;

Pochettino, A ;

Kotloff, RM .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (05) :735-740

[3] Pulmonary hypertension in interstitial lung disease [J].

Behr, J. ;

Ryu, J. H. .

EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (06) :1357-1367

[4] IMPROVEMENT IN PULMONARY-HYPERTENSION AND HYPOXEMIA DURING NITRIC-OXIDE INHALATION IN A PATIENT WITH END-STAGE PULMONARY FIBROSIS [J].

CHANNICK, RN ;

HOCH, RC ;

NEWHART, JW ;

JOHNSON, FW ;

SMITH, CM .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :811-814

[5] Eicosanoids: mediators and therapeutic targets in fibrotic lung disease [J].

Charbeneau, RP ;

Peters-Golden, M .

CLINICAL SCIENCE, 2005, 108 (06) :479-491

[6] Sildenafil improves walk distance in idiopathic pulmonary fibrosis [J].

Collard, Harold R. ;

Anstrom, Kevin J. ;

Schwarz, Marvin I. ;

Zisman, David A. .

CHEST, 2007, 131 (03) :897-899

[7] Elevated brain natriuretic peptide predicts mortality in interstitial lung disease [J].

Corte, T. J. ;

Wort, S. J. ;

Gatzoulis, M. A. ;

Engel, R. ;

Giannakoulas, G. ;

Macdonald, P. M. ;

Wells, A. U. .

EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (04) :819-825

[8]

Corte TJ, 2009, SARCOIDOSIS VASC DIF, V26, P7

[9] Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension [J].

Corte, T. J. ;

Wort, S. J. ;

Gatzoulis, M. A. ;

Macdonald, P. ;

Hansell, D. M. ;

Wells, U. .

THORAX, 2009, 64 (10) :883-888

[10] ATS statement: Guidelines for the six-minute walk test [J].

Crapo, RO ;

Casaburi, R ;

Coates, AL ;

Enright, PL ;

MacIntyre, NR ;

McKay, RT ;

Johnson, D ;

Wanger, JS ;

Zeballos, RJ ;

Bittner, V ;

Mottram, C .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) :111-117

← 1 2 3 4 5 6 7 →